GenVec, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1992-01-01
- Employees
- 15
- Market Cap
- -
- Website
- http://genvec.com
Clinical Trials
14
Active:5
Completed:8
Trial Phases
3 Phases
Phase 1:5
Phase 2:4
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (50.0%)Phase 2
4 (40.0%)Phase 3
1 (10.0%)TNFerade Biologic to Treat Locally Advanced Prostate Cancer
Phase 1
- Conditions
- Locally Advanced Prostate Cancer
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2012-03-12
- Lead Sponsor
- GenVec
- Target Recruit Count
- 20
- Registration Number
- NCT01048151
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Radiotherapy, Cetuximab, and Injections of TNFerade™ Biologic for Elderly or Frail Patients With Head and Neck Cancer
Phase 1
Completed
- Conditions
- Head and Neck CancerHead and Neck Neoplasms
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2012-02-23
- Lead Sponsor
- GenVec
- Registration Number
- NCT00496236
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
A Study of TNFerade™ Biologic With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) in Patients With Head and Neck Cancer
Phase 1
Completed
- Conditions
- Head and Neck CancerHead and Neck Neoplasms
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2012-02-23
- Lead Sponsor
- GenVec
- Registration Number
- NCT00496535
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
TNFerade™ Biologic Plus Radiation for Metastatic Melanoma
Phase 2
Completed
- Conditions
- Melanoma
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2011-05-12
- Lead Sponsor
- GenVec
- Registration Number
- NCT00261404
- Locations
- 🇺🇸
Mary Crowley Medical Research Center, Dallas, Texas, United States
A Study to Treat Patients Whose Chronic Angina Symptoms Are Not Relieved by Medication and Have an Area of the Heart That Cannot be Treated by Standard Therapies
Phase 2
Completed
- Conditions
- Moderate to Severe Angina Pectoris
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-05-13
- Lead Sponsor
- GenVec
- Target Recruit Count
- 129
- Registration Number
- NCT00215696
- Locations
- 🇩🇰
Cardiovascular Laboratory 2014, The Heart Center, University hospital Rigshospitalet, Copenhagen, Denmark
🇩🇰Skejby Sygehus, Caridology Laboratory, Århus N, Denmark
🇮🇱Cardiac Catheterization Laboratories, Cardiology Department, Rabin Medical Center, Petah, Tikva, Israel
- Prev
- 1
- 2
- Next
News
No news found